{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:08:33Z","timestamp":1788948513444,"version":"build-2803163510"},"reference-count":59,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Persistent infection with high-risk human papillomavirus (hrHPV) is the principal cause of cervical cancer and initiates a complex process of immune evasion that enables malignant progression despite continuous expression of the viral oncoproteins E6 and E7. Effective antitumor immunity depends on coordinated antigen presentation through human leukocyte antigen class I (HLA-I) molecules, activation of CD8+ cytotoxic T lymphocytes, and balanced regulation of immune responses. During cervical carcinogenesis, these mechanisms are progressively disrupted through HLA-I downregulation, CD8+ T-cell exhaustion, expansion of FOXP3+ regulatory T cells, and activation of the PD-1\/PD-L1 and CTLA-4 immune checkpoint pathways, ultimately establishing an immunosuppressive tumor microenvironment that promotes immune escape. This narrative review integrates current evidence on HLA-I-mediated antigen presentation, CD8+ cytotoxic T-cell function, FOXP3+ regulatory T cells, and immune checkpoint signaling into a unified model of immune escape during cervical carcinogenesis. In addition, it discusses the clinical implications of these interconnected mechanisms, including immune checkpoint inhibition, emerging therapeutic strategies, integrated immune profiling, and future directions in personalized immunotherapy. A comprehensive understanding of the interactions between antigen presentation, immune-cell function, and immune checkpoint regulation provides the biological foundation for current and future immunotherapeutic approaches. Integrating molecular, cellular, and spatial immune characteristics may improve patient stratification, optimize treatment selection, and facilitate the implementation of precision immuno-oncology in cervical cancer.<\/jats:p>","DOI":"10.3390\/ijms27188009","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:24:02Z","timestamp":1788945842000},"page":"8009","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated Immune Escape in Cervical Cancer: HLA-I Dysfunction and Immune Checkpoint Signaling"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7719-382X","authenticated-orcid":false,"given":"Angel","family":"Yordanov","sequence":"first","affiliation":[{"name":"Department of Gynaecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7109-607X","authenticated-orcid":false,"given":"Vasilena Dimitrova","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The estimated lifetime probability of acquiring human papillomavirus in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex. Transm. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1345","DOI":"10.1016\/S2214-109X(23)00305-4","article-title":"Global and regional estimates of genital human papillomavirus prevalence among men: A systematic review and meta-analysis","volume":"11","author":"Bruni","year":"2023","journal-title":"Lancet Glob. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.virol.2018.01.002","article-title":"Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61)","volume":"516","author":"Chen","year":"2018","journal-title":"Virology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Bosch","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice","volume":"97","author":"Khan","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kombe, A.J.K., Li, B., Zahid, A., Mengist, H.M., Bounda, G.A., Zhou, Y., and Jin, T. (2020). Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front. Public Health, 8.","DOI":"10.3389\/fpubh.2020.552028"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","article-title":"Papillomaviruses in the causation of human cancers\u2014A brief historical account","volume":"384","year":"2009","journal-title":"Virology"},{"key":"ref_10","first-page":"476","article-title":"HPV integration: Moving from carcinogenesis mechanisms to clinical applications","volume":"1","author":"Lai","year":"2025","journal-title":"Med. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cac2.12629","article-title":"Advances in cervical cancer: Current insights and future directions","volume":"45","author":"Xu","year":"2025","journal-title":"Cancer Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e29685","DOI":"10.1002\/jmv.29685","article-title":"High-risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects","volume":"96","author":"Calati","year":"2024","journal-title":"J. Med. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chaberek, K., Mrowiec, M., Kaczmarek, M., and Dutsch-Wicherek, M. (2022). The creation of the suppressive cancer microenvironment in patients with HPV-positive cervical cancer. Diagnostics, 12.","DOI":"10.3390\/diagnostics12081906"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1128\/JVI.79.23.14852-14862.2005","article-title":"Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6\/E7 is related to reduced macrophage inflammatory protein-3\u03b1 production","volume":"79","author":"Guess","year":"2005","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clim.2015.09.003","article-title":"Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C","volume":"161","author":"Woodham","year":"2015","journal-title":"Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1042\/BST20210961","article-title":"Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance","volume":"50","author":"Balasubramanian","year":"2022","journal-title":"Biochem. Soc. Trans."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","article-title":"Cancer immune escape: The role of antigen presentation machinery","volume":"149","author":"Kallingal","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e15509","DOI":"10.1111\/tan.15509","article-title":"Allelic loss of HLA class I facilitates evasion from immune surveillance in cervical intraepithelial neoplasia","volume":"103","author":"Kawase","year":"2024","journal-title":"HLA"},{"key":"ref_19","first-page":"1211","article-title":"Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma","volume":"19","author":"Ritz","year":"2001","journal-title":"Int. J. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40425-016-0184-3","article-title":"Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases","volume":"4","author":"Ferns","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00251-017-1011-9","article-title":"Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell \u201cmissing self\u201d recognition","volume":"69","author":"Malmberg","year":"2017","journal-title":"Immunogenetics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10656","DOI":"10.1073\/pnas.1100354108","article-title":"HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes","volume":"108","author":"Gooden","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.humimm.2012.07.041","article-title":"Human leukocyte antigen-G (HLA-G) expression in cervical cancer lesions is associated with disease progression","volume":"73","author":"Li","year":"2012","journal-title":"Hum. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Guo, W., Dai, L., and Qiu, L. (2025). T cell subsets in cervical cancer tumor microenvironment: Advances and therapeutic opportunities. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1612032"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhang, B., Liu, J., Mo, Y., Zhang, K., Huang, B., and Shang, D. (2024). CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: Key to the success of immunotherapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1476904"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Garcia-Becerra, N., Aguila-Estrada, M.U., Palafox-Mariscal, L.A., Hernandez-Flores, G., Aguilar-Lemarroy, A., and Jave-Suarez, L.F. (2023). FOXP3 Isoforms Expression in Cervical Cancer: Evidence about the Cancer-Related Properties of FOXP3\u03942\u03947 in Keratinocytes. Cancers, 15.","DOI":"10.3390\/cancers15020347"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e005151","DOI":"10.1136\/jitc-2022-005151","article-title":"T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer","volume":"10","author":"Ni","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yordanov, A., Damyanova, P., Vasileva-Slaveva, M., Karakadieva, K., Kostov, S., and Shivarov, V. (2025). Clinical significance of tumor infiltrating T-helper and regulatory cells in Bulgarian cervical cancer patients. Biomedicines, 13.","DOI":"10.3390\/biomedicines13092206"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41416-020-01184-x","article-title":"Infiltrating T-cell markers in cervical carcinogenesis: A systematic review and meta-analysis","volume":"124","author":"Litwin","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Javed, S.A., Najmi, A., Ahsan, W., and Zoghebi, K. (2024). Targeting PD-1\/PD-L1 immune checkpoint inhibition for cancer immunotherapy: Success and challenges. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1383456"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rotman, J., den Otter, L.A.S., Bleeker, M.C.G., Samuels, S.S., Heeren, A.M., Roemer, M.G.M., Kenter, G.G., Zijlmans, H.J.M.A.A., van Trommel, N.E., and de Gruijl, T.D. (2020). PD-L1 and PD-L2 expression in cervical cancer: Regulation and biomarker potential. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.596825"},{"key":"ref_33","first-page":"767","article-title":"Predictive values of PD-L1 expression for survival outcomes in patients with cervical cancer: A systematic review and meta-analysis","volume":"93","author":"Hu","year":"2022","journal-title":"Ginekol. Pol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3892\/ol.2024.14700","article-title":"PI3K\/AKT\/mTOR and PD-1\/CTLA-4\/CD28 pathways as key targets of cancer immunotherapy (Review)","volume":"28","author":"Wang","year":"2024","journal-title":"Oncol. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): A randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"115146","DOI":"10.1016\/j.ejca.2024.115146","article-title":"Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1\/GOG-3016\/ENGOT-cx9 trial","volume":"216","author":"Oaknin","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1470-2045(24)00088-3","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): A phase 1\u20132, open-label, multicohort trial","volume":"25","author":"Oaknin","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s44370-025-00019-8","article-title":"Novel therapeutic vaccine development strategies targeting high risk HPV16\/18-E6\/7 oncoproteins, their immunogenicity, and efficacy associated with cervical intraepithelial neoplasia and cervical cancer: A systematic review","volume":"2","author":"Teffera","year":"2025","journal-title":"Discov. Viruses"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e163841","DOI":"10.1172\/JCI163841","article-title":"SCCA1\/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production","volume":"133","author":"Chen","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Barrientos, N.T., Solorzano-Ibarra, F., Klimov-Kravtchenko, K., Rojas-Diaz, J.M., Guitron-Avina, M.S., Ceja-Flores, F.J., Cruz-Ramos, J.A., Ortiz-Lazareno, P.C., Bustos-Rodriguez, F.d.J., and Vazquez-Limon, J.C. (2025). T cell exhaustion in the cervical cancer tumor microenvironment: PD-1 overexpression and co-expression with TIGIT, Tim-3, LAG-3, and NKG2A. Cancers, 17.","DOI":"10.3390\/cancers17223627"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-022-01264-9","article-title":"Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1158\/0008-5472.CAN-04-1091","article-title":"Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection","volume":"64","author":"Kobayashi","year":"2004","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e011258","DOI":"10.1136\/jitc-2024-011258","article-title":"Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: A report from the SITC global access and impact committee","volume":"13","author":"Dent","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cac2.12023","article-title":"Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Su, Q., Tian, X., Li, F., Yu, X., Gong, W., Chen, Y., Wang, J., Yang, S., Zhang, S., and Zhang, Q. (2025). Integrated multi-omics analysis of single-cell and spatial transcriptomics reveals distinct HPV-associated immune microenvironment features and prognostic signatures in cervical cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1612623"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e012630","DOI":"10.1136\/jitc-2025-012630","article-title":"Oligoclonal tumor-specific CD8 T-cell revival and IRE1\u03b1\/XBP1-GDF15-mediated immunosuppressive niches determine neoadjuvant chemoimmunotherapy efficacy in cervical cancer","volume":"13","author":"Cao","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Mart\u00edn, E., Reina, G., and Carlos, S. (2025). Advances in therapeutic vaccines against HPV: A review of human clinical trials. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32110600"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: A randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: A phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13027-021-00395-y","article-title":"HPV16 E6-specific T cell response and HLA-A alleles are related to the prognosis of patients with cervical cancer","volume":"16","author":"Cai","year":"2021","journal-title":"Infect. Agents Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Draper","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Yu, L., Lanqing, G., Huang, Z., Xin, X., Minglin, L., Fa-Hui, L., Zou, H., and Min, J. (2023). T cell immunotherapy for cervical cancer: Challenges and opportunities. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1105265"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41746-024-01106-8","article-title":"Artificial intelligence in digital pathology: A systematic review and meta-analysis of diagnostic test accuracy","volume":"7","author":"McGenity","year":"2024","journal-title":"npj Digit. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Yuan, J., and Chen, L. (2026). Transforming cervical cancer pathological diagnosis through artificial intelligence: Progress, performance, and barriers to clinical implementation. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1716018"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8009\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:31:01Z","timestamp":1788946261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":59,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188009"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188009","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}